Last updated on February 2018

Study of BCMA CAR-T in Multiple Myeloma


Brief description of study

The purpose of this study is to infusion BCMA CAR-T cells to the patients with relapsed and refractory multiple myeloma(MM), to assess the safety and feasibility of this strategy. The CAR enables the T cell to recognize and kill the MM cells through the recognition of BCMA, a protein expressed of the surface of the malignant plasma cells in MM patients.

Clinical Study Identifier: NCT03322735

Find a site near you

Start Over